VILLA GUARDIA (COMO), Italy--(BUSINESS WIRE)--Dec. 7, 2005--Gentium S.p.A. (AMEX:GNT) (the “Company”) announced today that positive data from the Phase II trial with Defibrotide for the treatment of Veno-Occlusive Disease (“VOD”) and Multi-system Organ Failure (“MOF”) (“Severe VOD”) as a complication of bone marrow and stem cell transplantation (SCT) will be presented by Paul G. Richardson, M.D. in a paper entitled, “Defibrotide for the Treatment of Veno-Occlusive Disease (VOD) and Multi-System Organ Failure (MOF) Post SCT: Analysis of Response and Survival According to Degree and Type of MOF.” Dr. Richardson, Clinical Director of Dana Farber Cancer Institute’s Jerome Lipper Multiple Myeloma Center, Assistant Professor of Medicine at Harvard Medical School and principal investigator in the Phase II trial, will present the paper in a Simultaneous Oral Session on December 12, 2005 at 11:30 a.m. at the 2005 Annual Meeting of the American Society of Hematology (ASH). The meeting is to take place at the Georgia World Congress Center in Atlanta from December 10-13, 2005.
